Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3887062 | 0.86 | HTT (0.51) | RPS6KB1ROCK1RPS6KA1LMNAGPBAR1 | |
| SCHEMBL3888823 | 0.86 | GPBAR1 (0.65) | LMNAGPBAR1HTTTP53TSHR | |
| SCHEMBL4056646 | 0.84 | LMNA (0.53) | RPS6KB1ROCK1RPS6KA1LMNAGPBAR1 | |
| SCHEMBL7928701 | 0.82 | ADRA1A (0.52) | LMNAGPBAR1HTTTP53 | |
| SCHEMBL5661329 | 0.82 | ADRA1A (0.52) | LMNAGPBAR1HTTTP53 | |
| SCHEMBL8004288 | 0.82 | ADRA1A (0.52) | LMNAGPBAR1HTTTP53 | |
| SCHEMBL4312703 | 0.81 | RPS6KB1 (0.58) | RPS6KB1ROCK1RPS6KA1LMNAGPBAR1 | |
| SCHEMBL17478072 | 0.80 | LMNA (0.49) | RPS6KB1ROCK1RPS6KA1LMNAGPBAR1 | |
| SCHEMBL3342133 | 0.80 | LMNA (0.58) | RPS6KB1ROCK1RPS6KA1LMNAGPBAR1 | |
| SCHEMBL17782167 | 0.80 | TP53 (0.56) | LMNAGPBAR1TP53TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932309-B2 | 2-oxo-3,4-dihydropyridine-5-carboxylates and their use | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2018-04-03 | — | — | US | disclosed |
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-07-27 | — | — | US | disclosed |
| EP-3174872-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | Université de Lille 2 Droit et Santé (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016238-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210710-A1 | 2-OXO-3,4-DIHYDROPYRIDINE-5-CARBOXYLATES AND THEIR USE | CYP3A5, CYP2D6, QDPR | RPS6KB1 3039/4885ROCK1 4387/4885RPS6KA1 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.